Status of treatment and outcome in Kawasaki disease in the Kinki area of Japan.
Kawasaki disease
Z-score
acute treatment
coronary artery abnormality
epidemiology
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
15
09
2022
received:
16
04
2022
accepted:
14
10
2022
pubmed:
19
10
2022
medline:
28
12
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
The treatment guidelines for acute Kawasaki disease (KD) have been revised several times. Moreover, the criterion used to define coronary artery abnormalities (CAAs) has changed from the coronary artery's internal diameter to the Z-score. Treatment for KD and methods for evaluating CAAs vary between hospitals, so we investigated the actual status of acute KD treatment and development of CAAs under the 2012 Japanese treatment guidelines for acute KD. The 24th Japanese Nationwide Survey on Kawasaki Disease yielded 2618 patients who developed KD in the Kinki area in 2016. We sent a secondary questionnaire to each participating hospital and used the resulting data to investigate the frequency of CAAs according to Z-score, treatment by KD treatment stage, and predictors of CAAs. The response rate was 80.0%. The data for 1426 patients without major data deficiencies were examined. The frequency of CAAs was 3.0% when based on coronary artery internal diameters and 8.8% when based on Z-scores. Intravenous immunoglobulins combined with corticosteroids were administered as an initial treatment in 12.8% of cases and as a second-line treatment in 16.8% of cases. Corticosteroids, cyclosporine A, infliximab, and plasma exchange were used at similar frequencies for third-line treatment. A pretreatment maximum coronary artery Z-score of ≥1.9 and age <1 year were associated with significantly higher incidences of CAAs. Using the Z-score resulted in a threefold increase in the number of patients diagnosed with CAAs. A pretreatment maximum coronary artery Z-score of ≥1.9 and age <1 year are useful predictors of CAAs.
Sections du résumé
BACKGROUND
BACKGROUND
The treatment guidelines for acute Kawasaki disease (KD) have been revised several times. Moreover, the criterion used to define coronary artery abnormalities (CAAs) has changed from the coronary artery's internal diameter to the Z-score. Treatment for KD and methods for evaluating CAAs vary between hospitals, so we investigated the actual status of acute KD treatment and development of CAAs under the 2012 Japanese treatment guidelines for acute KD.
METHODS
METHODS
The 24th Japanese Nationwide Survey on Kawasaki Disease yielded 2618 patients who developed KD in the Kinki area in 2016. We sent a secondary questionnaire to each participating hospital and used the resulting data to investigate the frequency of CAAs according to Z-score, treatment by KD treatment stage, and predictors of CAAs.
RESULTS
RESULTS
The response rate was 80.0%. The data for 1426 patients without major data deficiencies were examined. The frequency of CAAs was 3.0% when based on coronary artery internal diameters and 8.8% when based on Z-scores. Intravenous immunoglobulins combined with corticosteroids were administered as an initial treatment in 12.8% of cases and as a second-line treatment in 16.8% of cases. Corticosteroids, cyclosporine A, infliximab, and plasma exchange were used at similar frequencies for third-line treatment. A pretreatment maximum coronary artery Z-score of ≥1.9 and age <1 year were associated with significantly higher incidences of CAAs.
CONCLUSIONS
CONCLUSIONS
Using the Z-score resulted in a threefold increase in the number of patients diagnosed with CAAs. A pretreatment maximum coronary artery Z-score of ≥1.9 and age <1 year are useful predictors of CAAs.
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15391Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 19H03904
Informations de copyright
© 2022 Japan Pediatric Society.
Références
Ae R, Makino N, Kosami K, Kuwabara M, Matsubara Y, Nakamura Y. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the Nationwide Survey in Japan, 2017-2018. J Pediatr. 2020;225:23-9.
Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery. Guidelines for medical treatment of acute Kawasaki disease [in Japanese]. Pediatr Cardiol Cardiac Surg. 2003;20:54-62.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. Lancet. 2012;379:1613-20.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153:833-8.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomized controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019;393:1128-37.
Mori M, Imagawa T, Katakura S, Miyamae T, Okuyama KI, Ito S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma globulin. Mod Rheumatol. 2004;14:43-7.
Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery. Guidelines for medical treatment of acute Kawasaki disease [in Japanese]. Gakkai Zasshi (Pediatr Cardiol Cardiac Surg). 2012;28:s1-28.
Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery. Guidelines for medical treatment of acute Kawasaki disease [in Japanese]. Gakkai Zasshi (Pediatr Cardiol Cardiac Surg). 2020;36:s1-29.
Kamiya T, Kawasaki T, Okuni M, Kato H, Baba K, Nakano H. Subcommittee for standardization of diagnosing coronary artery lesion in patients with Kawasaki disease, research Committee for Kawasaki Disease in the Ministry of Welfare and Health. Diagnostic criteria of cardiovascular complication after Kawasaki disease [in Japanese]; 1983: 1-10. [cited 2022 Apr 14]. Available from: http://www.niph.go.jp/wadai/mhlw/1983/s5805004.pdf
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics. 2004;114:1708-33.
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927-99.
Makino N, Nakamura Y, Yashiro M, Kosami K, Matsubara Y, Ae R, et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int. 2019;61:397-403.
Kobayashi T, Fuse S, Sakamoto N, Mikami M, Ogawa S, Hamaoka K, et al. A new Z-score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population. J Am Soc Echocardiogr. 2016;29:794-801.
Z score calculator of coronary arterial diameter. [Accessed 24 January 2022]. Available from: http://raise.umin.jp/zsp/calculator/#sub
Suzuki T, Kakimoto N, Tsuchihashi T, Suenaga T, Takeuchi T, Shibuta S, et al. Z-score is a possible predictor of the risk of coronary artery lesion development in patients with Kawasaki disease in Japan. Eur J Pediatr. 2021;180:2797-805.
Fuse S, Mori T, Kuroiwa Y, Hirakawa S. On what day of illness does the dilatation of coronary arteries in patients with Kawasaki disease begin? Circ J. 2018;82:247-50.
Son MB, Gauvreau K, Tremoulet AH, Lo M, Baker AL, de Ferranti S, et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a north American population. J Am Heart Assoc. 2019;8:e011319.
Manlhiot C, Millar K, Golding F, McCrindle BW. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol. 2010;31:242-9.
Tsuchihashi T, Kakimoto N, Takeuchi T, Suenaga T, Suzuki T, Shibuta S, et al. Intimal thickening and disruption of the media occur in the arterial walls of coronary arteries not associated with coronary arterial aneurysms in patients with Kawasaki disease. BMC Cardiovasc Disord. 2021;21:278.
Xie L, Yan W, Huang M, Huang MR, Chen S, Huang GY, et al. Epidemiologic features of Kawasaki disease in Shanghai from 2013 through 2017. J Epidemiol. 2020;30:429-35.
Ae R, Abrams JY, Maddox RA, Schonberger LB, Nakamura Y, Kuwabara M, et al. Outcomes in Kawasaki disease patients with coronary artery abnormalities at admission. Am Heart J. 2020;225:120-8.
Mossberg M, Mohammad AJ, Kahn F, Segelmark M, Kahn R. High risk of coronary artery aneurysm in Kawasaki disease. Rheumatology. 2021;60:1910-4.
Miyata K, Miura M, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, et al. Risk factors of coronary artery abnormalities and resistance to intravenous immunoglobulin plus corticosteroid therapy in severe Kawasaki disease: an analysis of post RAISE. Circ Cardiovasc Qual Outcomes. 2021;14:e007191.
Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, et al. Risk factors of coronary artery aneurysms in Kawasaki disease with a low risk of intravenous immunoglobulin resistance: an analysis of post RAISE. J Pediatr. 2022;240:158-163.e4.
Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, et al. Analysis of age, sex, lack of response to intravenous immunoglobulin, and development of coronary artery abnormalities in children with Kawasaki disease in Japan. JAMA Netw Open. 2022;5(6):e2216642.
Takahashi K, Oharaseki T, Yokouchi Y, Naoe S, Saji T. Kawasaki disease: basic and pathological findings. Clin Exp Nephrol. 2013;17:690-3.